Primary Ovarian Insufficiency Support Protocol

Women's Health/EndocrineLimited Evidence
6
supplements
2
Primary
4
Supporting
0
Grade A
44
Studies

Primary Stack

Core supplements with strongest evidence
2000-4000 IU daily (titrate to levels)

Critical for bone health; POI increases osteoporosis risk; often deficient

8 studies400 participants
1000-1200mg daily (diet + supplement)

Essential for bone health; estrogen deficiency accelerates bone loss

10 studies600 participants

Supporting Stack

Additional supplements for enhanced results
25-75mg daily (under medical supervision)

May support ovarian function and improve fertility outcomes in some cases

8 studies400 participants
200-600mg daily

Supports mitochondrial function in oocytes; being studied for fertility

5 studies200 participants
2-3g EPA+DHA daily

Cardiovascular protection; estrogen deficiency increases CV risk

8 studies400 participants
300-400mg daily

Supports bone health; may help with mood and sleep disturbances

5 studies200 participants

How This Protocol Works

Simple Explanation

Primary Ovarian Insufficiency (POI), previously called premature ovarian failure, occurs when the ovaries stop functioning normally before age 40. This leads to irregular periods, low estrogen, and often infertility.

KEY FEATURES:

•Occurs before age 40
•Irregular or absent periods
•Symptoms of estrogen deficiency (hot flashes, vaginal dryness)
•Elevated FSH levels (>25 IU/L on two occasions)
•Reduced fertility (though spontaneous pregnancy possible in ~5%)

CAUSES:

•Unknown in most cases (idiopathic)
•Genetic conditions (Turner syndrome, Fragile X carrier)
•Autoimmune disorders
•Chemotherapy or radiation
•Surgical removal of ovaries

CRITICAL: POI requires medical management for hormone replacement and associated health risks. This protocol is SUPPORTIVE ONLY.

MEDICAL MANAGEMENT:

•Hormone replacement therapy (HRT): Essential until typical menopause age
•Estrogen + progesterone: Protects bone, heart, brain, vaginal health
•Fertility options: Egg donation most successful; IVF with own eggs sometimes possible
•Bone health monitoring: DEXA scan; prevent osteoporosis
•Cardiovascular risk: Monitor lipids, blood pressure

LONG-TERM HEALTH CONCERNS:

•Osteoporosis (early estrogen loss damages bones)
•Cardiovascular disease (estrogen is protective)
•Cognitive effects
•Sexual and vaginal health
•Emotional impact

* Vitamin D and calcium are critical for bone health.

* DHEA may support ovarian function (discuss with specialist).

* Cardiovascular protection with omega-3 and healthy lifestyle.

Expected timeline: HRT provides immediate symptom relief. Bone and cardiovascular protection requires ongoing management. Supplements support overall health alongside HRT.

Clinical Perspective

Primary Ovarian Insufficiency: Cessation of ovarian function before 40. Diagnosis: elevated FSH (>25 IU/L x 2, 4-6 weeks apart), oligo/amenorrhea >4 months, age <40. Affects 1% of women. Causes: idiopathic (most), genetic (FMR1, Turner), autoimmune, iatrogenic.

CRITICAL: HRT (estrogen + progesterone) is standard of care until typical menopause age (~50) - reduces bone loss, CVD risk, vasomotor symptoms. Test: karyotype, FMR1, thyroid, adrenal antibodies. Fertility: spontaneous pregnancy 5-10%; egg donation most effective. Bone health: DEXA at diagnosis; calcium, vitamin D essential. DHEA controversial but some evidence for fertility. Supplements supportive only - do not replace HRT.

* Vitamin D (B-grade): Bone health. Review: (PMID: 28750270). 2000-4000 IU daily.

* Calcium (B-grade): Bone health. Guidelines: (PMID: 28332116). 1000-1200mg daily.

* DHEA (C-grade): Ovarian support. Systematic review: (PMID: 25111582). 25-75mg daily (supervised).

* CoQ10 (C-grade): Oocyte mitochondria. Review: (PMID: 24268541). 200-600mg daily.

* Omega-3 (B-grade): CV protection. Review: (PMID: 27840029). 2-3g EPA+DHA daily.

* Magnesium (C-grade): Bone/mood. Review: (PMID: 28445426). 300-400mg daily.

Assessment targets: Hormone levels, bone density, lipid panel, symptom control, fertility status.

Protocol notes: HRT: essential; start at diagnosis; continue until age 50; reduces mortality. Estrogen: oral or transdermal; physiologic doses (not contraceptive doses). Progesterone: required if uterus present. Fertility: egg donation success rate ~50% per cycle; own eggs possible but low success. DHEA: if pursuing fertility, 6-16 weeks before IVF. Genetic testing: FMR1 (Fragile X) affects family counseling; karyotype if Turner suspected. Autoimmune: check thyroid, adrenal antibodies; may have other autoimmune conditions. Bone: DEXA at diagnosis; repeat q2-3 years. CV risk: lifestyle, lipids, BP monitoring. Psychological: significant emotional impact; counseling helpful. Support groups: POI-specific resources valuable.